IDRA-21
Cognitive · Ampakine
Tier D
Bottom line
Read Off Label grades IDRA-21 as D (3.3/10) based on preclinical only evidence, unclear benefit magnitude, and a unclear-risk safety profile.
Cortex Pharmaceuticals-era compound.
Studied, labeled, or reported-use context: No established human dosing — Research chem; not individualized guidance.
What the evidence says
Cortex Pharmaceuticals-era compound. Primate cognition data (Baboons — Buccafusco) but no human trials. Typical ampakine concerns: seizure threshold lowering with chronic or high-dose use.
Mechanism
Benzothiadiazide ampakine; positive allosteric modulator of AMPA receptors; slows receptor desensitization; parent compound of the benzothiadiazide ampakine class
Studied, labeled, or reported dose & route
No established human dosing
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about IDRA-21's effects?
- Read Off Label rates the evidence for IDRA-21 as Preclinical only and the benefit magnitude as unclear, producing an overall grade of D (3.3/10). Cortex Pharmaceuticals-era compound.
- What safety findings are reported for IDRA-21?
- IDRA-21 has a unclear risk profile in the database. Unknown (no human safety; AMPA seizure risk concern) Legal status: Research chem.
- What doses or routes are reported for IDRA-21?
- No established human dosing This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does IDRA-21 work?
- Benzothiadiazide ampakine; positive allosteric modulator of AMPA receptors; slows receptor desensitization; parent compound of the benzothiadiazide ampakine class
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.